| |
Release Date
07/27/2012 |
|
| Expiration Date
07/27/2013 |
| |
|
|
| |
|
|
| |
 |
|
Kimberly Brown, MD
Henry Ford Hospital
Detroit, MI |
|
| |
| |
 |
|
Robert Brown, MD, MPH
Columbia University Department of Medicine
New York, NY |
|
| |
| |
 |
|
| |
 |
|
| |
Jointly sponsored by the Purdue University College of Pharmacy and the Chronic Liver Disease Foundation. |
|
| |
|
|
| |
This activity
supported by: |
|
| |
Program supported by an educational grant from Salix Pharmaceuticals. |
|
| |
|
|
|
|
|
| Target Audience |
| This activity has been designed to meet the educational needs of transplant surgeons, gastroenterologists, physician assistants, and nurse practitioners involved in the care of patients with HE. |
| |
| Statement of Need/Program
Overview |
| The primary goal of this webcast is to review clinical implications of new data on the management and treatment of Hepatic Encephalopathy (HE) in patients with chronic liver disease. |
| |
| Educational Objectives |
| At the conclusion of this initiative, participants will do the following: |
|
• |
Describe the common complications of cirrhosis and the prognostic importance of hepatic encephalopathy (HE) |
| • |
Evaluate the impact of HE on the quality of life of patients with cirrhosis |
| • |
Apply the most current body of evidence to clinical decision making in the management of HE |
| • |
Assess data suggesting that cognitive impairment associated with overt HE may not be completely reversible |
|
| |
| Physician Accreditation
Statement |
| This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and the Chronic Liver Disease Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians. |
| |
| Credit Designation |
| Purdue University College of Pharmacy designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
| |
| Disclosure Statement |
| All faculty and staff involved in the planning or presentation of continuing education activities sponsored/ provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Focus Medical Communications staff, Chronic Liver Disease Foundation staff and Purdue University College of Pharmacy staff have no relationships to disclose. |
| |
| Faculty Disclosure Statement |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and the Chronic Liver Disease Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Kim Brown, MD
Kim Brown, MD has disclosed that she has received grants/research support from Bayer/Onyx, BMS, CDC Foundation, Genentech, Hyperion, Ikaria, Novartis and Schering Plough. Dr. Brown has also served as a consultant and on the Speaker’s Bureau for Ad Boards, Bayer, Blue Cross, Genentech, Gilead, Onyx, Merck, Roche, Salix Pharmaceuticals and Vertex. She has also held an Advisory Board Membership for Gliead, Merck and Salix Pharmaceuticals.
Robert Brown, MD, MPH
Bob Brown, MD, MPH has disclosed that he has received grants/research support from Salix Pharmaceuticals and Hyperion. Dr. Brown has also served as a consultant and on the Speaker’s Bureau for Salix Pharmaceuticals. |
| |
 |
| |
|
